LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma

This study is using liquid biopsy — a blood test that detects cancer DNA — to monitor and diagnose whether aggressive B-cell lymphoma (a blood cancer) has spread or is likely to spread to the brain or spinal fluid (central nervous system). Researchers hope this non-invasive test can replace or complement more painful spinal taps. **You may be eligible if...** - You have been newly diagnosed with one of the following: high-risk DLBCL (with specific risk features), high-grade B-cell lymphoma with MYC and BCL2/BCL6 rearrangement, Burkitt lymphoma, certain mantle cell lymphoma subtypes, or primary CNS lymphoma - You have not yet started treatment - You are treated at one of the participating centers in Switzerland **You may NOT be eligible if...** - You have already received systemic lymphoma treatment - You have a low-risk lymphoma subtype not meeting the study criteria - You are unable to provide informed consent Talk to your doctor to see if this trial is right for you.